

CROHN'S/ UC REFERRAL FORM

Phone: 888-292-0744 hionlusry com

A careton company										DIC	piusi	X.COIII	
PATIENT INFORMATION													
Patient's Name:				SSN:					DOB:				
Address:			City:	City:				State: Zip:					
Home Phone: Cell:			Heigh	Height: We			eight:			Gender:	Male	Female	
Email			Diagnosis Code:										
INSURANCE INFORMATION (or c	ıttach cop	y of the cards)											
Primary Insurance:	1	Policy Holder:	R	elation	ship:		Poli	icy #:		Group) #:		
Secondary Insurance:	1	Policy Holder:	R	elation	ship:		Pol	icy #:		Group	#:		
PRESCRIPTION INFORMATION (fo	or IV medi	cation attach a copy of	the pre	escrip	otion)					'			
AMJEVITA™ (adalimumab-atto) □ SureClick 40 mg/0.8 mL □ Prefilled Syringe 20 mg/0.4 mL □ Prefilled Syringe 40 mg/0.8 mL nduction: 160 mg SubQ Day 1 □ 4 x 40 mg SubQ in one day □ 2 x 40 mg SubQ per day for two consecutive days □ 2 x 40 mg SubQ Day 15 Refills: 0 ###################################				SIMPONI® (golimumab) □ Prefilled Syringe □ Autoinjector □ Induction: 200 mg (2 x 100 mg) SubQ at week 0 Qty: 2 syringes Refills: 0 SKYRIZI™ (risankizumab-rzaa)									
□ 40 mg SubQ every other week Refills: □ □ □ □ ClMZIA® (certolizumab pegol) □ Prefilled Syringe □ □ Lyophilized Powder □ Induction: 400 mg (2 x 200 mg) SubQ weeks 0, 2, 4 Refills: 0 Refills: 0 Class Class			OBI										
DUPIXENT® (dupilumab) Prefilled Syringe Pen Induction: Inject 2 x 300 mg (600 mg) SubQ Day 1 Duy: 2 for 14 days Refills: None Maintenance: Inject 300 mg SubQ every other week Duy: 2 for 28 days Refills:			City: Refills: 0 Maintenance: Starting 8 weeks after IV induction dose, 90 mg SubQ every 8 weeks City: 1 SOLESTA® (dextranomer and sodium hyaluronate) 1 ml Prefilled Syringe 4 submucosal injections City: 4 Refills: Refills:										
Entocort® (budesonide) B mg capsules 9 mg PO daily 2ty: 90 Refills:			UCERIS 9 mg Qty: 30			mg Extende	d-Releas	se Tablet					
HUMIRA® (adalimumab) ☐ Pen ☐ Drefilled Syringe ☐ Citrate Free (CF) ☐ Original Formula nduction: ☐ 160 mg SubQ day 1, 80 mg SubQ day 15			XELJANZ® (tofacitinib) ☐ Induction: 10 mg PO twice daily for 8-16 week ☐ Uty: Refills: Refills: ☐ Maintenance: 5 mg PO twice daily ☐ Waintenance: 5 mg PO twice daily ☐ Refills: ☐ S50 mg tablet										
□ 80 mg SubQ day 1, 80 mg SubQ day 2/ 80 mg SubQ day 15 □ the state of the state				□ 550 mg PO three times per day for 14 days □ 200 mg PO three times per day for 16 days □ mg POtimes per day fordays Qty:Refills:									
RINVOQ® (upadacitinib) extended-release tablets □ 15 mg □ 30 mg □ 45 mg nduction: □ 45 mg PO once daily for 8 weeks □ 45 mg PO once daily for 12 weeks 2ty: 2 bottles Refills: 0 □ Maintenance: mg once daily Refills: □				ZEPOSIA® (ozanimod) ☐ 7-day titration: days 1-4: Give 0.23 mg PO once daily. days 5 to 7: Give 0.46 mg PO daily Qty: 1 Refills: None ☐ Maintenance Dosing: Starting day 8, 0.92 mg PO once daily Qty: 30 Refills:									
MMUNOSUPPRESSIVE INFUSION □ AVSOLA® □ ENTYVIO® □ Initial Dose:mg/kg at □ other:mg/kg every	mab	mg/kg every 8 weeks Refills:											
□ OTHER STRENGTH:	SIG/D	IRECTIONS:						REFILLS:	: (QUANTI	TY:		
s required by your state, Prescriber to check "In sign to prevent generic substitution.	Dispense as wr	itten" or handwrite "Brand Medically	Necessar	y" [☐ Dispense	as written							
PHYSICIAN INFORMATION			Injectio	on Tra	aining:	Offic	ce to Ir	nstruct	SP to	o Arranç	ge <u>Tea</u>	ching	
Prescriber Name:		Phone:				Fax:				•			
Office Contact:			Email:										
Address:					Ship To: Patient MD Office								
NPI #:				Tax ID#:									
Prescription Signature:						Date:							

BSP230721